Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) PT Raised to $87 at Leerink Partners
October 30, 2024 6:26 AM EDTLeerink Partners analyst Andrew S. Berens raised the price target on Incyte (NASDAQ: INCY) to $87.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This morning, Incyte reported 3Q24 financial results and provided updates on the pipeline. INCY beat consensus on key product revenues, with... More
Incyte (INCY) PT Raised to $97 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Incyte (NASDAQ: INCY) to $97.00 (from $92.00) while maintaining a Buy rating.
The analyst comments "Incyte reported 3Q24 results, delivering topline revenue beats due to sustained growth for key franchise drivers in Jakafi and... More
Incyte (INCY) PT Raised to $84 at Jefferies
October 29, 2024 2:41 PM EDTJefferies analyst Kelly Shi raised the price target on Incyte (NASDAQ: INCY) to $84.00 (from $81.00) while maintaining a Buy rating.
The analyst comments "INCY delivered great Q with rev beat ($1.14B vs $1.08B cons) all around - Jakafi $741M (+5% QoQ vs $718M cons) and... More
